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Abstract
Background: Matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of
arterial aneurysms through increased proteolysis of extracellular matrix proteins. Increased
proteolysis due to elevated matrix degrading enzyme activity in the arterial wall may act as a
susceptibility factor for the development of coronary aneurysms. The aim of this study was to
investigate the association between MMPs and presence of coronary aneurysms.
Methods: Thirty patients with aneurysmal coronary artery disease and stable angina were enrolled
into study (Group 1). Fourteen coronary artery disease patients with stable angina were selected
as control group (Group 2). MMP-1, MMP-3 and C-reactive protein (CRP) were measured in
peripheral venous blood and matched between the groups.
Results: Serum MMP-3 level was higher in patients with aneurismal coronary artery disease
compared to the control group (20.23 ± 14.68 vs 11.45 ± 6.55 ng/ml, p = 0.039). Serum MMP-1
(13.63 ± 7.73 vs 12.15 ± 6.27 ng/ml, p = 0.52) and CRP levels (4.78 ± 1.47 vs 4.05 ± 1.53 mg/l, p =
0.13) were not significantly different between the groups.
Conclusion: MMPs can cause arterial wall destruction. MMP-3 may play role in the pathogenesis
of coronary aneurysm development through increased proteolysis of extracellular matrix proteins.
Introduction
Coronary artery aneurysms are defined as dilated coro-
nary artery segments that are greater than 1.5 times the
diameter of adjacent normal segments [1,2]. The gold
standard for diagnosing this type of aneurysm is coronary
angiography, which provides information about the size,
shape, location and number of aneurysms.
Coronary aneurysms may occur during the development
of coronary atherosclerosis. Previous studies have shown
that coronary aneurysms are observed in 1% to 5% of
patients with angiographic evidence of coronary artery
disease [3-6]. In some studies, coronary aneurysms have
been associated with an increased risk of myocardial inf-
arction [3,4]. Although the mechanisms responsible for
coronary aneurysm formation during the atherosclerotic
process are unclear, atherosclerosis-induced aneurysms
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derive primarily from thinning and/or destruction of the
media [6-8].
Possible factors contributing to aneurysms are matrix-
degrading enzymes such as collagenases, gelatinases, and
stromelysins [9,10]. More specifically, matrix metallopro-
teinases (MMPs) are enzymes that can degrade the struc-
tural proteins of connective tissue. Degradation of
extracellular matrix proteins may weaken the connective
tissue, thereby leading to a weakened vascular wall.
We investigated the association between MMPs and coro-
nary artery aneurysm by measuring the levels of MMP-1
and MMP-3 (both of which represent markers of proteo-
lytic activity) in patients with coronary artery disease,
some of whom had coronary aneurysms (cases) and oth-
ers who did not (controls).
Methods
Patient population
We reviewed the medical records of patients who had
undergone coronary angiography between January, 2002
and April, 2003. Among 4,456 cases reviewed, 55 patients
(1.23%) diagnosed with aneurysmal coronary artery dis-
ease were selected. Sixteen patients with acute coronary
syndromes and nine patients with balloon angioplasty
history were excluded from the study. The remaining 30
patients with aneurysmal coronary artery disease patients
were enrolled into the study. Transverse diameter of an
aneurysm and reference vessel were measured using the
post-processing software (Schimadzu Corporation, DIGI-
TEX ALPHA Plus System, Kyoto, Japan, 2001). The ratio
between dilated coronary artery segment and reference
vessel diameter was calculated. The control patients (n =
14) had coronary artery disease, but were free of aneurys-
mal coronary dilatation. Both groups had positive exercise
stress tests and had been diagnosed with stable angina.
Blood biochemistry and echocardiography were per-
formed in all patients. No patient had a history of coro-
nary atherectomy or balloon angioplasty. All participants
gave informed consent.
Autoimmune disease, inflammatory arteritis, chronic or,
acute infectious disease, use of steroid or anti-inflamma-
tory drugs within the last three months, renal failure and
cancer were accepted as exclusion criteria.
Laboratory assays
Specimen collection
Fasting blood samples (8–10 hours fast) were obtained
from the antecubital vein at approximately 9:00 a.m.
These were centrifuged for 10 min at 3,000 × g at a tem-
perature of about 4°C. Serum was stored at -70°C. Blood
samples were analyzed at the Ege University Department
of Microbiology, Section of Serology.
Assay protocol for MMP-1 and MMP-3
MMP levels were determined using enzyme-linked immu-
nosorbent assay (ELISA) kits, according to the manufac-
turer's instructions (MMP-1, Biotrak Amersham
Pharmacia Biotech, United Kingdom; RPN 2610; MMP-3,
Biotrak Amersham Pharmacia Biotech, United Kingdom;
RPN 2613). The ELISA kit measured total MMP-1 (pro
MMP-1, free MMP-1, MMP1/tissue inhibitor MP-1 com-
plex), total MMP-3 (pro MMP-3, free MMP-3, MMP3/tis-
sue inhibitor MP-1 and MMP3/tissue inhibitor MP-2
complex) at >89% cross reactivity. Samples were incu-
bated in microtitre wells pre-coated with anti-MMP-1
(lyophilized rabbit anti-MMP-1) and anti-MMP-3 (perox-
idase labelled Fab antibody to MMP-3) antibodies. The
assays use the pro form of a detection enzyme that can be
activated (by captured active MMP) into an active detec-
tion enzyme. MMP-1 and MMP-3 can be measured in the
range of 6.25–100 ng/ml and 3.75–120 ng/ml, respec-
tively. The results received from the optic scanners at 450
nm were converted into ng/ml values from a standard
curve. All samples were run in duplicate and were aver-
aged. Within-assay precision values for duplicate determi-
nations were 5.5%, 7.9% and 7.3% at MMP-1
concentrations of 16.89 ± 0.94 ng/ml, 35.53 ± 2.82 ng/ml
and 54.08 ± 4.0 ng/ml, respectively. Between-assay preci-
sions for repeated measurements of the same sample were
11.6%, 12.0% and 13.2% at MMP-1 concentrations of
23.19 ± 2.68 ng/ml, 55.27 ± 6.65 and 98.04 ± 12.93,
respectively. The within-assay precisions for duplicate
determinations were 4.8%, 2.4% and 2.1% at MMP-3
concentrations of 13.7 ± 0.66 ng/ml, 33.7 ± 0.83 ng/ml
and 83.2 ± 1.76 ng/ml, respectively. Between-assay preci-
sions for repeated measurement of the same sample were
13.3%, 11.7% and 8.8% at MMP-3 concentrations of 11.2
± 1.49 ng/ml, 27.6 ± 3.24 and 75.4 ± 6.63, respectively.
Determination of C-reactive protein levels
Serums were obtained by centrifugation of vacutainer-
clotted tubes at 3,000 rpm for 10 minutes. High sensitivity
C-reactive protein (hs-CRP) samples were stored at -30°C
and analyzed by latex particle-enhanced immunoturbidi-
metric assay. The total median inter-assay and intra-assay
coefficients of variation for the assays were <6% for CRP.
All results were recorded in the patients' files.
Statistical analyses
All values are reported as mean ± SD. Chi Square test was
used in the comparison of categorical variables while stu-
dent unpaired-t test or Mann-Whitney Rank Sum tests
were used, where appropriate, in the univariate analysis.
Statistical analyses were performed with SPSS statistical
software. A value of p < 0.05 was considered to be statisti-
cally significant.Current Controlled Trials in Cardiovascular Medicine 2004, 5:10 http://cvm.controlled-trials.com/content/5/1/10
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Results
There were no significant differences in baseline character-
istics between cases and controls. High-density lipopro-
tein, low-density lipoprotein, total cholesterol and
triglyceride levels were not statistically different between
the groups. Clinical characteristics of and medication use
by the groups are shown in Table 1.
Mean serum MMP-1 (13.63 ± 7.73 vs 12.15 ± 6.27 ng/ml,
p = 0.52) and CRP levels (4.78 ± 1.47 vs 4.05 ± 1.53 mg/
l, p = 0.13) were not significantly different between cases
and controls. Mean serum MMP-3 values were signifi-
cantly higher in the cases than in controls (20.23 ± 14.68
and 11.45 ± 6.55 ng/ml respectively, p = 0.039). MMP-1,
MMP-3 and hs-CRP levels are shown in Figure 1.
Discussion
Essential factors contributing to the formation of coronary
aneurysms include vessel media degradation and ulcera-
tion due to increased proteolytic activity. Connective tis-
sue integrity, another factor contributing to aneurysm
development, depends on the balance between degrada-
tion and repair of the extracellular matrix. Activation or
inhibition of degrading enzymes affects extracellular
matrix modeling [9,10], which, in turn, affects connective
tissue and vascular wall integrity.
Matrix-degrading enzyme activity is a tightly controlled
process that involves transcription, activation of latent
pro-enzymes and inhibition of proteolytic activity [11-
13]. A key step in the regulation of MMPs may occur at the
level of transcription [14]. The mechanism by which gene
transcription is mediated is thought to involve a prostag-
landin E2(PGE2)-cAMP- dependent pathway. G-proteins
have been implicated in this pathway [15]. Transcription
activity can be stimulated by a variety of inflammatory
cytokines, hormones, and growth factors [16-19]. Several
factors are also known to inhibit MMP gene expression
and these include indomethacin, corticosteroids, and
interleukin-4 [17,20,21].
MMP activity is also regulated by tissue-specific inhibitors.
There are four known tissue inhibitors of metalloprotein-
ases (TIMP-1, -2, -3 and -4). The TIMPs are secreted by a
Table 1: Clinical Characteristics and Medication Use of Study Participants
Group 1 (n = 30) Group 2 (n = 14) p
Mean age (yrs) 55.2 ± 10.0 51.8 ± 7.7 NS
Male sex % (n) 70%(21) 64%(9) NS
Diabetes Mellitus % (n) 13%(4) 14%(2) NS
Hypertension % (n) 30%(9) 21%(3) NS
Smoking % (n) 60%(18) 50%(7) NS
TC (mg/dl) 196.8 ± 31.7 195.1 ± 38.2 NS
TG (mg/dl) 148.7 ± 71.2 151.7 ± 64.0 NS
HDL-C (mg/dl) 46.7 ± 11.8 50.7 ± 13.0 NS
LDL-C (mg/dl) 125.1 ± 28.2 116.7 ± 34.2 NS
hs-CRP (mg/L) 4.78 ± 1.47 4.05 ± 1.53 NS
MMP-1 (ng/ml) 13.63 ± 7.73 12.15 ± 6.27 NS
MMP-3 (ng/ml) 20.23 ± 14.68 11.45 ± 6.55 0.039
Baseline therapy
Aspirin 73%(22) 64%(9) NS
Nitrate 57%(17) 64%(9) NS
Statin 17%(5) 21%(3) NS
Number of stenotic vessels
One vessel disease 37%(11) 36%(5) NS
Two vessel disease 50%(15) 43%(6) NS
Three vessel disease 13%(4) 21%(3) NS
Reference vessel diameter (mm) 2.95 ± 0.48 - -
Aneurysm vessel diameter (mm) 4.78 ± 0.93 - -
Aneurysm/reference vessel ratio 1.6 ± 0.1 - -
Aneurysm segment
Right coronary artery 53%(16) - -
Left anterior descending artery 27%(8) - -
Left Circumflex artery 30%(9) - -
Group 1:Patients with coronary aneurysm, Group 2:Patients without coronary aneurysm, TC:Total cholesterol, TG:Triglyceride, HDL-C:High-
density lipoprotein cholesterol, LDL-C:Low-density lipoprotein cholesterol, hs-CRP:High sensitivity C- reactive protein, MMP-1:Matrix 
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variety of cell lines, including smooth muscle cells and
macrophages. Their activity is increased by growth factors
and either increased or decreased by different interleukins
[22]. Increased levels of MMP-2, MMP-3, MMP-9 and
MMP-12 have been identified in aneurysm vessel walls
[23-27]. Gene disruption of MMP-9 suppresses the devel-
opment of experimental abdominal aortic aneurysms
[28]. Conversely, decreased levels of TIMPs have been
found in the aneurysm wall [26]. Allaire et al. [29]
reported that local expression of TIMP-1 may prevent aor-
tic aneurysm degeneration and rupture in a rat model.
Carrell et al. [30] examined differences in MMPs between
patients with aortic aneurysm and patients with aortic
atherosclerosis but without aneurysm. Among a wide
range of MMPs tested, only MMP-3 was over-expressed in
the aortic aneurysm samples. Reduced aneurysm forma-
tion has been observed in mice with MMP-3 gene inacti-
vation [31]. Finally, the recent observation that high
circulating levels of MMP-3 are associated with coronary
lesions in Kawasaki disease [32] also supports an impor-
tant role for MMP-3 in the pathogenesis of coronary aneu-
rysms. These data suggest that proteolytic balance in the
vascular wall plays a key role in aneurysm development.
MMP-1 (interstitial collagenase) and MMP-3 (strome-
lysin-1) are members of a family of proteinases that
degrade one or more components of the extracellular
matrix. In our study, it appears that elevated MMP-3 activ-
ity may represent a risk factor for coronary aneurysm for-
mation. This finding is concordant with previously
published studies. The mechanisms underlying this asso-
ciation are unclear. MMP-3 gene disruption may be
responsible. Lamblin et al. [33] have reported similar
findings, namely, that the MMP-3 5A allele is associated
with the occurrence of coronary aneurysm.
Others have reported that MMP-3 is expressed in athero-
sclerotic plaque cells, but not by cells in normal arteries
[34-37]. In addition, extensive inflammation and destruc-
tion of musculo-elastic vessel wall elements have been
observed in dilated human coronary arteries [38,39]. Sch-
oenhagen et al. [40] suggest that the degradation of extra-
cellular matrix by MMP-3 may contribute to the
expansion of the coronary vessel wall. This effect is
characteristic of positive remodeling. Based on these and
our own observations, we maintain that MMP-3 over-
expression may occur in aneurysm segments. Histopatho-
caption Figure 1Current Controlled Trials in Cardiovascular Medicine 2004, 5:10 http://cvm.controlled-trials.com/content/5/1/10
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logic studies would be needed to clarify whether or not
this is the case.
MMP levels are elevated in patients with acute myocardial
infarction, unstable angina and coronary angioplasty
[35,41,42]. All patients in our study had been diagnosed
with stable angina before being enrolled into the study.
CRP reflects systemic inflammatory activity. In this study,
we did not observe increased CRP levels in those patients
with coronary aneurysms. One explanation for similar
CRP expression between cases and controls might be that
all study subjects had been diagnosed with stable angina
pectoris.
Varying degrees of inflammation are reported among
individuals with abdominal aortic aneurysms. This varia-
tion may relate to possible confounding due to clinical
manifestations (asymptomatic or symptomatic) and
aneurysm progression rates (cm/year). Other investigators
have failed to observe increased CRP levels among asymp-
tomatic patients with abdominal aortic aneurysm [43].
Because elevated MMP-3 levels likely contribute to the
development of coronary aneurysms, this matrix-degrad-
ing enzyme may represent an important therapeutic tar-
get. Luan et al. [44] reported that a number of statins
inhibit MMP-3 activity in rabbits. COX-2 inhibitors may
also suppress MMP expression. Production of MMPs by
macrophages occurs through a PGE2/cAMP-dependent
pathway [45]. Theoretically, COX-2 inhibitors could
attenuate this pathway. Another target of MMP inhibition
has been demonstrated in animal models of adenovirus-
mediated TIMP gene transfer [46].
In reporting our findings, we acknowledge that measure-
ment of TIMP levels between cases and controls would
have provided useful information about the possibility of
proteolytic imbalance. Similarly, measurement of locally
produced inflammatory cytokines, hormones and growth
factors would be interesting to know about, since these
regulate matrix-degrading enzyme expression [16-19].
This could provide relevant information, as systemic
inflammatory activity may not reflect local inflammatory
infiltration in aneurysm segments. Finally, the study
would have benefited from having a larger sample size as
well as genotype determination.
We conclude that MMP-3 overexpression due to a proteo-
lytic imbalance may lead to coronary aneurysm develop-
ment through degradation of matrix components,
especially lamina elastica. New medical therapeutic
options targeted specifically against MMP-3 may prove
useful in the prevention of aneurysm formation.
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